Sernova (FRA:PSH) NonCurrent Deferred Liabilities : €0.00 Mil (As of Jan. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sernova NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Sernova's non-current deferred liabilities for the quarter that ended in Jan. 2024 was €0.00 Mil.

Sernova NonCurrent Deferred Liabilities Historical Data

The historical data trend for Sernova's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova NonCurrent Deferred Liabilities Chart

Sernova Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

NonCurrent Deferred Liabilities

Get a 7-Day Free Trial

Sernova Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Sernova NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Sernova's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sernova (FRA:PSH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Corp (FRA:PSH) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

SEOVF:USA PSH:Germany SVA:Canada

Address

700 Collip Circle, The Stiller Centre, Suite 114, London, ON, CAN, N6G 4X8

Website

https://www.sernova.com

Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and or hormones for the long-term treatment of multiple serious, chronic diseases such as diabetes, hemophilia, and thyroid disease.